Analysis of Competitive Barriers Between BrightGene BioMed's T-Bren and Enhertu in the Adjuvant Therapy Field

Based on the collected information, I will conduct a systematic analysis for you.

---

Currently, the global HER2 ADC space is undergoing profound transformation. AstraZeneca/Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), supported by positive results from the DESTINY clinical trial program, has gradually advanced from third-line to second-line and first-line therapy, and successfully expanded its scope to adjuvant and neoadjuvant therapy[1]. Data from the phase III DESTINY-Breast05 study showed that Enhertu reduced the risk of disease recurrence or death by 53% compared to the standard of care T-DM1, with a 3-year invasive disease-free survival (IDFS) rate of 92.4%, significantly outperforming the 83.7% rate in the T-DM1 group[2].

Facing the strong competitive barriers built by Enhertu in frontline therapy, most domestic HER2 ADC companies have adopted differentiated strategies—focusing on later-line therapy or drug-resistant settings. However, BrightGene BioMed’s T-Bren (BL-M07D1) has chosen to compete head-on: its adjuvant therapy for HER2-positive breast cancer has advanced to phase III clinical trials, and neoadjuvant therapy is in phase II clinical trials, forming a direct rivalry with Enhertu’s core development trajectory[1].

---

ADC drugs consist of three components: antibody, linker, and payload. Technological optimization of each component constitutes a core competitive barrier:

Enhertu uses Daiichi Sankyo’s proprietary DXd topoisomerase I inhibitor, which is approximately 1,000 times more cytotoxic than traditional chemotherapy drugs and exhibits a bystander effect—capable of killing surrounding tumor cells that do not directly bind to the target[2]. Although T-Bren is also a topoisomerase I inhibitor-based ADC, it needs to demonstrate pharmacodynamic properties equivalent or superior to DXd in terms of payload molecular design, and the balanced optimization of toxicity intensity and selectivity.

Enhertu uses a stable cleavable tetrapeptide linker that remains highly stable in the bloodstream, releasing the payload only within tumor cells to achieve precise killing[2]. T-Bren needs to achieve equivalent or better stability metrics in linker design while ensuring effective release in the tumor microenvironment—this technical balance is a key determinant of ADC efficacy and safety.

The DAR value directly impacts the efficacy and toxicity of an ADC. Enhertu has a DAR value of approximately 8, achieving a good balance between efficacy and safety. T-Bren needs to determine the optimal DAR value through systematic optimization and maintain batch-to-batch consistency in large-scale production.

---

To compete head-on with Enhertu in the adjuvant therapy space, T-Bren needs to conduct large-scale, long-term follow-up phase III head-to-head clinical trials. The DESTINY-Breast05 study enrolled 1,635 patients with a median follow-up time of nearly 30 months[2]. T-Bren’s clinical trial design must meet the same rigorous standards in terms of enrollment criteria, follow-up duration, and efficacy endpoints.

The adjuvant therapy space has extremely high requirements for long-term drug safety. Enhertu has accumulated extensive long-term safety data, with an incidence rate of interstitial lung disease (ILD)/non-infectious pneumonia of approximately 9.6%, most of which are low-grade events[2]. T-Bren needs to demonstrate its safety profile in a sufficiently large patient population, particularly its ability to control rare but serious adverse events.

The primary efficacy endpoints for adjuvant therapy are typically disease-free survival (DFS) or invasive disease-free survival (IDFS), which require a long follow-up period to obtain mature survival data. T-Bren needs to demonstrate that its efficacy is non-inferior or even superior to Enhertu, which requires a longer clinical development cycle and a larger patient enrollment scale.

---

The manufacturing of ADC drugs involves complex bioconjugation processes, which have extremely high requirements for production facilities and quality control systems:

• Consistency of Bioconjugation Process
  : Ensure high consistency of DAR values and conjugation sites across all batches
• Purification Process Control
  : Effectively remove impurities such as free payload and aggregates
• Cold Chain Logistics System
  : ADC drugs typically require cold chain transportation and storage
• Production Capacity Scale
  : Meet global commercial supply demands

---

Despite the aforementioned technical barriers, BrightGene BioMed has designed multiple differentiated competitive paths for T-Bren:

In addition to breast cancer, T-Bren has demonstrated “best-in-class” potential in non-small cell lung cancer (NSCLC). In the Ib/II phase study presented at the 2025 ESMO Congress, T-Bren achieved an objective response rate (ORR) of 62.0% and a confirmed objective response rate (cORR) of 54.0% in previously treated patients with HER2-mutated advanced NSCLC; the 6-month duration of response (DoR) rate reached 95.7%, and the 6-month progression-free survival (PFS) rate was 90.7%[1]. This cross-indication layout can mitigate competitive risks associated with a single indication.

---

T-Bren is currently advancing 14 clinical trials simultaneously in China and the US, including 6 pivotal registration studies[1]. This global layout helps to:

• Obtain safety data from diverse ethnic groups
• Submit new drug applications to multiple regulatory authorities simultaneously
• Lay the foundation for subsequent global commercialization

---

BrightGene BioMed has built a comprehensive technology platform covering bispecific ADCs, dual-payload ADCs, immunostimulatory payload ADCs, and antibody-radionuclide conjugates (ARCs)[3]. Iza-bren (an EGFR×HER3 bispecific ADC) has made breakthrough progress in later-line nasopharyngeal carcinoma therapy, and its technical experience can support the optimization of T-Bren.

---

For T-Bren to effectively compete with Enhertu in the adjuvant therapy space, it needs to break through the following key nodes:

Barrier Dimension	Core Challenge	Breakthrough Path
Clinical Efficacy	Demonstrate non-inferiority to Enhertu	Large-scale head-to-head phase III study, long-term follow-up data
Safety	Establish differentiated safety advantages	Optimize ADC structure, reduce incidence of serious adverse events (AEs) such as ILD
Manufacturing	Consistency in large-scale production	Build GMP-compliant ADC production facilities
Commercialization	Build global commercialization capabilities	Strategic partnerships or establish in-house commercial team
Differentiation	Avoid homogeneous competition	Cross-indication layout, explore combination therapy regimens

Zhu Yi, founder of BrightGene BioMed, stated that it will take at least 5 years and an investment of USD 1 billion to become a truly international enterprise[3]. In terms of global R&D, BrightGene BioMed has established an innovative R&D center in Zhangjiang, Pudong, Shanghai, which will collaborate with its US R&D center to build a global R&D pattern driven by both China and the US.

---

The head-to-head competition between T-Bren and Enhertu in the adjuvant therapy space is, in essence, a comprehensive contest of the integrated technical capabilities of ADC drugs. T-Bren needs to achieve breakthroughs in multiple dimensions including ADC structural design, clinical development, and manufacturing, while building differentiated competitive advantages through cross-indication layout and global development. Despite facing the first-mover advantages and data barriers established by Enhertu, BrightGene BioMed still has the potential to secure a position in this highly competitive track by virtue of its technical platform accumulation and strategic resolve.

---

[1] China Pharmaceutical Innovation and Research Development Association - HER2 ADC Market Consolidation: Live or Die for Domestic Players? (https://www.phirda.com/artilce_41347.html)

[2] AstraZeneca/Daiichi Sankyo - Phase III DESTINY-Breast05 Trial Results (https://www.astrazeneca.com/content/az-cn-zh/media/press-releases/2025/10-21-02.html)

[3] Pharmcube - BrightGene BioMed: Holding a Bispecific ADC “Blockbuster”, Accelerating the Sprint to the Global Market (https://bydrug.pharmcube.com/news/detail/3efa137ece4e6c48d862200838e97600)